Exploring How ADCs Enhance Anti-Tumor Immunity – Society for Immunotherapy of Cancer
Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:
“SITC25 Science Preview: Explore immunological dimensions of ADCs with Claire Friedman, MD, Eli Lilly, Alfred ZIppelius, MD, University Hospital Basel, Margaret K. Callahan, MD, PhD, The University of Connecticut School of Medicine, Paolo Tarantino, MD, Dana-Farber Cancer Institute – Harvard Medical Center and Greg Thurber, PhD, University of Michigan.
Presentations will highlight how ADCs may potentiate anti-tumor immunity, reprogram the tumor microenvironment, and overcome resistance, even in immunologically silent tumors. Through mechanistic insight and clinical translation, this session aims to reframe ADCs not just as targeted cytotoxics, but as immune-modulatory agents in the immunotherapy era.
View session details and register for SITC’s 40th Anniversary Annual Meeting․”
Proceed to the video attached to the post.
More posts featuring Society for Immunotherapy of Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023